Why I'm more eager than ever to buy Sonic Healthcare shares following earnings

My conviction in Sonic Healthcare is stronger than before. Here's why I'll be adding more to my portfolio to try to beat the market.

| More on:
A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Earnings for this healthcare giant were slashed by a colossal 54% in the first half, yet I'm hungrier than ever for more Sonic Healthcare Ltd (ASX: SHL) shares.

On Thursday, shares in the laboratory, pathology, and radiology services provider blasted 14.2% higher despite revenue and profits cratering. On top of that, the figures presented missed consensus estimates by 1%.

Created with Highcharts 11.4.3Sonic Healthcare PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

So, why on earth would I be wanting to increase my stake in Sonic Healthcare now?

At present, the company holds a 1% weight in my portfolio. Ideally, I'd now like to grow that position to between 2% to 3%… and here's my reasoning.

The COVID comedown

It's no secret that COVID-19 testing provided a temporary tailwind to Sonic's top and bottom lines. We are now seeing that fade away as we return to our 'new normal'. The diminishing COVID revenues have been an anchor on the Sonic Healthcare share price over the past year.

This might be unnerving for some shareholders. However, I take solace in the fact the core business is now fundamentally stronger than it was prior to the PCR testing frenzy.

As noted in its first-half results, Sonic's 'base business revenue' — comprising of laboratory, pathology, radiology, etc. revenue excluding COVID-19 testing — increased by 9% compared to the prior corresponding period to $3.7 billion.

Prior to 2020, the company had been growing its top line at around 10% per annum on average. I think there is an underappreciation for this base revenue. While it's not a trendy new industry, the diagnostic services market is incredibly large and estimated to grow at a compound annual growth rate (CAGR) of 13% out to 2030.

Where will Sonic Healthcare find growth?

I believe Sonic Healthcare will be able to sustain its 10% revenue growth by expanding into higher value — and possibly more in-demand — areas of diagnostics such as genetic, microbiome, and molecular diagnostics.

Molecular diagnostics

Speaking of molecular diagnostics: this is an area of diagnostics that Ark Invest highlighted in its Big Ideas 2023 report.

Analysts at Ark estimate the total addressable market for this type of diagnostic testing for cancer alone could be US$95 billion. Likewise, annual revenue derived from this form of testing is forecast to grow above 20% per annum through 2030 and beyond.

Source: Big Ideas 2023, Ark Invest

My guess is this played a key role in Sonic's decision to acquire ProPath in 2021. ProPath is a specialist in molecular pathology, serving 1,000 physicians and more than 20 hospital groups in the United States.

Hence, the addition of ProPath taps into the potential growth engine of molecular diagnostics — enabling a path for more upside in Sonic Healthcare shares.

Aging population

In my opinion, Sonic Healthcare could also grow faster for longer than most investors think due to an aging population. As people live longer as a byproduct of medical advancements, the rate of occurrence of cancers could trend higher.

As pictured above, the burden of cancer is estimated to increase by more than 60% from 2018 to 29.4 million new cases globally in 2040. In turn, I believe the demand for genetic predisposition testing, diagnosis, and prognosis of cancers will similarly expand over the next two decades.

There was an early indicator of the high growth rate in this market within Sonic's half-year presentation. In the US, revenue growth from ThyroSeq (thyroid cancer genetic test) was above 25%.

The potential reacceleration of earnings growth from this structural tailwind plays a significant role in my desire to buy more Sonic Healthcare shares.

What else is appealing about Sonic Healthcare shares?

There are a few others reasons why I personally see more upside to this global healthcare giant. To avoid this article becoming more of a novel, I'll list these additional positive factors below:

  • Despite COVID-19 testing revenue diminishing, molecular testing for various viruses will undoubtedly persist in the future.
  • The company is positioned for further inorganic growth as management utilised COVID-19 profits to deleverage its balance sheet.
  • Plenty of runway for increased dividends or more buybacks

Lastly, my ultra bull case for Sonic Healthcare shares is centred around where value will accumulate along the value chain in the future.

I believe there is potential for laboratory testing to absorb a greater proportion of attributed value as the industry pivots to a preventive approach, rather than reactive. Greater margins could be recognised by the likes of Sonic as a result.

This is quite a speculative assumption. Realistically, such a scenario is purely the 'cream on top' of my investment thesis.

Motley Fool contributor Mitchell Lawler has positions in Sonic Healthcare. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Opinions

Could Soul Patts shares hit $50 in 2025?

This company jumped more than 16% yesterday.

Read more »

A male investor sits at his desk looking at his laptop screen holding his hand to his chin pondering whether to buy Macquarie shares
Opinions

3 great lessons I learned being an owner of Brickworks shares

I’m going to take these lessons with me.

Read more »

A bricklayer peers over the top of a brick wall he is laying with a level measuring tool on top and looks critically at the work he is carrying out.
Opinions

The pros and cons of the Soul Patts and Brickworks merger

This is a big deal. What are the positives and negatives of the merger?

Read more »

Piggy bank at the end of a winding road.
Opinions

My top 3 picks in the ASX 20 in June

I think these stocks stand out from the rest of the ASX 20 pack.

Read more »

A woman is very excited about something she's just seen on her computer, clenching her fists and smiling broadly.
Opinions

Potential buys: 2 compelling ASX shares I like

I think both of these investments are appealing.

Read more »

An ASX 200 market analyst holds his hand to his chin and looks closely at his computer screens watching share price movements
Opinions

Forget term deposits! I'd buy these two ASX 200 stocks instead

I think ASX stocks could make a much better investment than term deposits.

Read more »

share buyers, investors, happy investors
ETFs

How I would build a $100,000 portfolio with ASX ETFs today

You don't need more than three ETFs to build a diversified portfolio...

Read more »

iPhone with the logo and the word Google spelt multiple times in the background.
Opinions

I've been buying these 2 US stocks in 2025. Here's why

Sometimes the US markets are a better place to go shopping for stocks.

Read more »